Radiopharmaceutical developer Navidea Biopharmaceuticals has posted revenue increases for its fiscal 2016 (end-December).
Revenues for the year were $22 million, compared with $13.2 million in 2015. Revenues consisted of $17 million in Lymphoseek sales, $3.1 million from federal grants, and $1.8 million from license agreements. Fourth-quarter 2016 revenues were $3.4 million, compared with $4.3 million for the same period in 2015.
The firm's net loss for the year was $14.3 million, compared with $27.6 million in 2015. Its net loss for the quarter was $3.9 million, compared with $2.5 million the previous year.
